Switching on kinases: oncogenic activation of BRAF and the PDGFR family
- 1 September 2004
- journal article
- research article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 4 (9) , 718-727
- https://doi.org/10.1038/nrc1434
Abstract
The cytoplasmic serine/threonine kinase BRAF and receptor tyrosine kinases of the platelet-derived growth factor receptor (PDGFR) family are frequently activated in cancer by mutations of an equivalent amino acid. Structural studies have provided important insights into why these very different kinases share similar oncogenic hot spots and why the PDGFR juxtamembrane region is also a frequent oncogenic target. This research has implications for other kinases that are mutated in human tumours and for the treatment of cancer using kinase inhibitors.Keywords
This publication has 79 references indexed in Scilit:
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFPublished by Elsevier ,2004
- KIT Mutations Are Common in Testicular SeminomasPublished by Elsevier ,2004
- Proteomic Approaches to the Analysis of Early Events in Colony-stimulating Factor-1 Signal TransductionMolecular & Cellular Proteomics, 2003
- The role of FLT3 in haematopoietic malignanciesNature Reviews Cancer, 2003
- High frequency of BRAF mutations in neviNature Genetics, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- Lucky draw in the gene raffleNature, 2002
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tractMolecular Reproduction and Development, 1997
- Steel Factor and c-kit Protooncogene: Genetic Lessons in Signal TransductionCritical Reviews™ in Oncogenesis, 1994